Table of Content

Chapter 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

Chapter 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Top player positioning, 2017
3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Increase in prevalence of arthritis
3.4.1.2. Growth in geriatric population
3.4.1.3. High demand for topical pain relief products by sportsperson
3.4.1.4. Lesser side effects caused by topical pain relief products as compared to oral medicines

3.4.2. Restraints

3.4.2.1. Topical pain relief sometimes cause skin irritants
3.4.2.2. Topical pain relief is characterized by unpleasant odor

3.4.3. Opportunities

3.4.3.1. Emergence of online pharmacy

3.4.4. Impact analysis

3.5. U.S. patent analysis by year (2014-2019)

Chapter 4: U.S. TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS

4.1. Overview

4.1.1. Market size and forecast

4.2. Non-opioids

4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by type

4.2.2.1. Nonsteroidal anti-inflammatory drugs (NSAIDS)

4.2.2.1.1. Market size and forecast

4.2.2.2. Methyl salicylates

4.2.2.2.1. Market size and forecast

4.2.2.3. Capsaicin

4.2.2.3.1. Market size and forecast

4.2.2.4. Lidocaine

4.2.2.4.1. Market size and forecast

4.2.2.5. Other non-opioids

4.2.2.5.1. Market size and forecast

4.3. Opioids

4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by type

4.3.2.1. Buprenorphine

4.3.2.1.1. Market size and forecast

4.3.2.2. Fentanyl

4.3.2.2.1. Market size and forecast

Chapter 5: U.S. TOPICAL PAIN RELIEF MARKET, BY FORMULATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Cream

5.2.1. Market size and forecast

5.3. Gel

5.3.1. Market size and forecast

5.4. Spray

5.4.1. Market size and forecast

5.5. Patch

5.5.1. Market size and forecast

5.6. Others

5.6.1. Market size and forecast

Chapter 6: U.S. TOPICAL PAIN RELIEF MARKET, BY TYPE

6.1. Overview

6.1.1. Market size and forecast

6.2. Prescription pain relief

6.2.1. Market size and forecast

6.3. Over-the-counter pain relief

6.3.1. Market size and forecast

Chapter 7: U.S. TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL

7.1. Overview

7.1.1. Market size and forecast

7.2. Pharmacies & drug stores

7.2.1. Market size and forecast

7.3. e-Commerce

7.3.1. Market size and forecast

7.4. Retail & grocery stores

7.4.1. Market size and forecast

Chapter 8: COMPANY PROFILES

8.1. AdvaCare Pharma

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product Portfolio

8.2. GlaxoSmithKline plc.

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product Portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments

8.3. Johnson & Johnson

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product Portfolio
8.3.5. Business performance

8.4. Nestl? S.A.

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product Portfolio
8.4.5. Business performance

8.5. Novartis AG

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product Portfolio
8.5.5. Business performance

8.6. Pfizer Inc.

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product Portfolio
8.6.5. Business performance

8.7. Reckitt Benckiser Group plc

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product Portfolio
8.7.5. Business performance

8.8. Sanofi

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product Portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments

8.9. Sun Pharmaceutical Industries Ltd.

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments

8.10. Topical BioMedics, Inc.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product Portfolio
8.10.5. Key strategic moves and developments



List of Figures



FIGURE 01. U.S. TOPICAL PAIN RELIEF MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP PLAYER POSITIONING, 2017
FIGURE 04. ESTIMATED AND PROJECTED NUMBER OF ADULTS WITH DOCTOR-DIAGNOSED ARTHRITIS IN THE U.S., 2000-2040 (MILLION)
FIGURE 05. NUMBER OF ELDERLY POPULATION (ADULT 65+) IN THE U.S., 2016-2060 (MILLION)
FIGURE 06. IMPACT ANALYSIS
FIGURE 07. U.S. PATENT ANALYSIS, BY YEAR
FIGURE 08. GSK: REVENUE, 2016–2018 ($MILLION)
FIGURE 09. GSK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 10. GSK: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 11. J&J: REVENUE, 2016–2018 ($MILLION)
FIGURE 12. J&J: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 13. J&J: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 14. NESTL?: REVENUE, 2016–2018 ($MILLION)
FIGURE 15. NESTL?: REVENUE SHARE BY OPERATING SEGMENT, 2018 (%)
FIGURE 16. NESTL?.: REVENUE SHARE BY REGIONREGION, 2018 (%)
FIGURE 17. NOVARTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 18. NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 19. NOVARTIS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 20. PFIZER: REVENUE, 2016–2018 ($MILLION)
FIGURE 21. PFIZER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 22. PFIZER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 23. RB: REVENUE, 2016–2018 ($MILLION)
FIGURE 24. RB: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 25. RB: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 26. SANOFI: NET SALES, 2016–2018 ($MILLION)
FIGURE 27. SANOFI: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 28. SANOFI: REVENUE SHARE BY REGIONREGION, 2018 (%)
FIGURE 29. SUN PHARMA: NET SALES, 2016–2018 ($MILLION)
FIGURE 30. SUN PHARMA: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 31. SUN PHARMA: REVENUE SHARE BY REGION, 2018 (%)
 

 

List of Tables



TABLE 01. U.S. TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2017–2025 ($MILLION)
TABLE 02. U.S. TOPICAL NON-OPIOIDS MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 03. U.S. TOPICAL OPIOIDS MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 04. U.S. TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017–2025 ($MILLION)
TABLE 05. U.S. TOPICAL PAIN RELIEF MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 06. U.S. TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 07. ADVACARE: COMPANY SNAPSHOT
TABLE 08. ADVACARE: BUSINESS SEGMENTS
TABLE 09. ADVACARE: PRODUCT PORTFOLIO
TABLE 10. GSK: COMPANY SNAPSHOT
TABLE 11. GSK: OPERATING SEGMENTS
TABLE 12. GSK: PRODUCT PORTFOLIO
TABLE 13. J&J: COMPANY SNAPSHOT
TABLE 14. J&J: OPERATING SEGMENTS
TABLE 15. J&J: PRODUCT PORTFOLIO
TABLE 16. NESTL?: COMPANY SNAPSHOT
TABLE 17. NESTL?: OPERATING SEGMENTS
TABLE 18. NESTL?: PRODUCT PORTFOLIO
TABLE 19. NOVARTIS: COMPANY SNAPSHOT
TABLE 20. NOVARTIS: OPERATING SEGMENTS
TABLE 21. NOVARTIS: PRODUCT PORTFOLIO
TABLE 22. PFIZER: COMPANY SNAPSHOT
TABLE 23. PFIZER: OPERATING SEGMENTS
TABLE 24. PFIZER: PRODUCT PORTFOLIO
TABLE 25. RB: COMPANY SNAPSHOT
TABLE 26. RB: OPERATING SEGMENTS
TABLE 27. RB: PRODUCT PORTFOLIO
TABLE 28. SANOFI: COMPANY SNAPSHOT
TABLE 29. SANOFI: OPERATING SEGMENTS
TABLE 30. SANOFI: PRODUCT PORTFOLIO
TABLE 31. SUN PHARMA: COMPANY SNAPSHOT
TABLE 32. SUN PHARMA: OPERATING SEGMENTS
TABLE 33. SUN PHARMA: PRODUCT PORTFOLIO
TABLE 34. TOPICAL BIOMEDICS: COMPANY SNAPSHOT
TABLE 35. TOPICAL BIOMEDICS: OPERATING SEGMENTS
TABLE 36. TOPICAL BIOMEDICS: PRODUCT PORTFOLIO